
Globus Medical (GMED) Stock Forecast & Price Target
Globus Medical (GMED) Analyst Ratings
Bulls say
Globus Medical Inc. shows strong potential for growth driven by faster than expected spine market expansion and increased sales in its Enabling Technologies segment, which could enhance overall profit margins. The company is currently trading below historical valuation levels, boasting impressive free cash flow (FCF) growth and an 8% FCF yield, which reinforces a favorable risk-reward scenario. Despite a recent earnings miss, the outlook remains positive with expectations for continued profit growth and resilience in the core business amid adverse market conditions.
Bears say
Globus Medical faces several critical risks that contribute to a negative outlook on its stock, including potential slower growth in the spine market, revenue dis-synergies from its merger with NuVasive, and disappointing sales within its Enabling Technologies segment. Fundamental concerns also arise from anticipated declines in operating margins and challenges related to key product launches and expansion efforts in the musculoskeletal space. As a result, revenue growth could decelerate to low-single digits, hindering margin expansion and overall financial performance.
This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.
Globus Medical (GMED) Analyst Forecast & Price Prediction
Start investing in Globus Medical (GMED)
Order type
Buy in
Order amount
Est. shares
0 shares